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OBJECTIVE: Chagas’ disease has spread throughout Latin America because of the high rate of migration among
these countries. Approximately 30% of Chagas’ patients will develop cardiomyopathy, and 10% of these will
develop severe cardiac damage leading to heart failure. Beta-blockade improves symptoms and survival in heart
failure patients; however, its efficacy has not been well established in Chagas’ disease. We evaluated the role of
carvedilol in cardiac remodeling and mortality in a Chagas’ cardiomyopathy animal model.
METHODS: We studied Trypanosoma cruzi infection in 55 Syrian hamsters that were divided into three groups:
control (15), infected (20), and infected + carvedilol (20). Animals underwent echocardiography, electrocardio-
graphy, and morphometry for collagen evaluation in ventricles stained with picrosirius red.
RESULTS: The left ventricular diastolic diameter did not change between groups, although it was slightly larger in
infected groups, as was left ventricular systolic diameter. Fractional shortening also did not change between groups,
although it was slightly lower in infected groups. Collagen accumulation in the interstitial myocardial space was
significantly higher in infected groups and was not attenuated by carvedilol. The same response was observed in the
perivascular space. The survival curve showed significantly better survival in the control group compared with the
infected groups; but no benefit of carvedilol was observed during the study. However, in the acute phase (up to 100
days of infection), carvedilol did reduce mortality.
CONCLUSION: Carvedilol did not attenuate cardiac remodeling or mortality in this model of Chagas’
cardiomyopathy. The treatment did improve survival in the acute phase of the disease.
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INTRODUCTION
Chagas’ disease was first described in the beginning
of the 20th century by Carlos Chagas (1). However, the
isolation of Trypanosoma cruzi DNA from the mummies of
humans who lived in the Atacama Desert in Chile and Peru
demonstrated that this disease may have affected human
beings for 9,000 years (2).
Based on cross-sectional surveys, the prevalence of T. cruzi
infection in Latin America is estimated to be as high as 17
million cases, and approximately 100 million people are at
risk of being infected. Additionally, the incidence of Chagas’
disease is estimated to be 700,000 new cases/year, and it
causes approximately 45,000 deaths annually (3). Because of
the high rates of migration from Latin America to nonen-
demic regions, such as North America and Europe, T. cruzi
infection has spread through blood transfusions, organ
transplantations, and congenitally (4,5). Based on this spread
of the disease, the World Health Organization launched The
Global Network for Chagas’ Disease Elimination (6).
Chronic Chagas’ cardiomyopathy may affect 30% of
infected patients, and 10% of these patients will develop
serious heart dysfunction with severe heart failure. The
histopathological findings in the chronic stage are focal
myocarditis that leads to myocyte loss, structural remodel-
ing with intense fibrosis, geometric changes, and ventricular
dysfunction. Several pathways have been proposed for the
progression and development of chronic cardiomyopathy.
Among them, in particular, is the sympathetic denervation
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of the heart in Chagas’ patients. It is characterized by diffuse
nervous tissue damage, parasitic invasion of preganglionic
neurons, and degenerative abnormalities in Schwann cells
and nerve fibers (7). Parasympathetic nerves and paraver-
tebral sympathetic ganglia are also involved (8). Some
studies have also demonstrated extremely decreased cardiac
beta-receptor density in Chagas’ cardiomyopathy (9).
Moreover, a clinical study (10) demonstrated decreased
norepinephrine content in myocardial tissue in Chagasic
patients.
Several clinical trials using a variety of beta-receptor
blockers have demonstrated improvements in symptoms,
ventricular function, functional capacity, and survival in
patients with heart failure (11-13). Based on these data,
patients with Chagas’ cardiomyopathy who develop heart
failure should benefit from this treatment. However, none of
these beta-blocker studies has included patients with
Chagas’ cardiomyopathy.
Therefore, because Chagas’ cardiomyopathy is a sympa-
thetic denervated heart disease with decreased adrenergic
activities, we hypothesized that beta-blockers may not
have the same benefits on cardiac structure, geometry, and
function, as described for other causes of heart failure. We
evaluated the effects of carvedilol on cardiac remodeling and
mortality in an animal model of Chagas’ cardiomyopathy.
MATERIAL AND METHODS
Animal Infection
We studied 55 outbred six-week-old female Syrian ham-
sters after T. cruzi infection. These animals were divided into
three groups: (1) normal control (c-15), (2) infected hamster
(inf-20), and (3) infected hamster treated with carvedilol
10 mg/kg/day given by gavage (infcv-20), with the dose
increased to 15 mg/kg/day after six months. The dosage
adjustment was made because of unexpected but not
significant heart rate decreases. The treatment began one
week after T. cruzi inoculation. All of the infected animals
were peritoneally inoculated with 3.5x105 T. cruzi Y strain
blood trypomastigotes and kept in a regular cage with water
and food ad libitum (14). The protocol was performed in
accordance with the recommendations of COBEA (the
Brazilian College of Experimental Animal Studies) and the
Guide for the Care and Use of Laboratory Animals (UFAW)
(15,16). The study protocol was reviewed and approved by
the ethical committee (SDC#2432/04/052; CAPPesq#0473/
04) of the Heart Institute and University of Sa˜o Paulo Medical
School.
The animals were euthanized after 11 months of infection
using intracardiac 3 M potassium chloride under 2,2,2-
tribromoethanol anesthesia. The heart was removed
through a median sternotomy and weighed. A portion of
the cardiac tissue was fixed in 10% formalin, and another
portion was frozen in liquid nitrogen and kept at -80 C˚. The
tibia length (mm) was measured for normalization of the
geometrical echocardiography parameter and heart weight
because it was a long-term study, and body weight loss
among infected animals could interfere with the results.
Echocardiography
All of the animals underwent a 2-D echocardiography
with M-mode and color Doppler before and at 4, 8, and 11
months after the infection. Briefly, the animal was perito-
neally infused with 2,2,2-tribromoethanol (2 g/kg) and
positioned as requested for easy accessibility of the
transducer. Transthoracic echocardiography was performed
using a Sequoia model 512 (Acuson, Mountain View, CA)
equipped with a 13-MHz linear transducer. The heart was
imaged in 2-dimensional mode in the parasternal long-axis,
short-axis, and 4-chamber view. Left ventricular end
diastolic diameter (LVEDD) and left ventricular systolic
diameter (LVESD) were obtained, and the result was
divided by tibia length, resulting in an index of LVEDD
and LVESD. Left ventricle (LV) systolic function was
assessed based on fractional shortening (FS). Global left
ventricular function was evaluated by the myocardial
performance index (MPI). For isovolumetric relaxation time
(IRT), a 5-chamber view of the heart was used to obtain the
sample volume position to straddle the left ventricle outflow
tract and mitral orifice. The formula IRT/!RR gave the
corrected IRT (CIRT) (17).
Electrocardiography
All of the animals underwent electrocardiography (ECG)
before and at four, eight, and 11 months after infection at the
same time as echocardiography. We used an automatic ECG
EP-3 (Dixtal Biome´dica, Sa˜o Paulo, SP, Brazil) and con-
nected the electrodes to the front and back paws, using the
right and left legs and arms as references. We analyzed DI,
DII, DIII, aVR, aVL and aVF with 2 N gain, 50 mm/s
velocity and conventional acquisition for 20 sec. The heart
rate, QRS duration, number of premature ventricular
complexes, and cardiac rhythm were analyzed.
Collagen morphology and morphometry
Serial paraffin sections (5 mm) of the formalin-fixed heart
tissues were stained with fibrillar collagen-specific picrosir-
ius red. Stained coronal sections from both ventricles were
then viewed by light microscopy to identify sites of fibrosis,
including those in the interstitial and perivascular space.
The interstitial collagen volume fraction (ICVF) and
perivascular collagen volume fraction (PCVF) for both
ventricles were determined by video morphometry using
a Quantimet 520 Image Analyses System (Leica, Inc.;
Deerfield, IL, USA) (18). All of the measurements were
taken by two independent and blinded examiners.
Statistical analysis
Data from each group were compared using the analysis
of variance (ANOVA) or Kruskal-Wallis tests according to
the normality of the sample. Tukey’s test or Dunn’s method
was used to identify differences. Survival curves were
constructed, and the log rank test was used to compare
them. The data are presented as the mean¡SEM and p-
values,0.05 were considered significant.
RESULTS
Clinical evaluation
The animals in the infected group were sick, with some
changes in their pile, and they remained clustered together
in the cage. They tended to be prostrate and less active. In
the 11th month, the body weight was higher in the infected
group than in the control and carvedilol groups (C:
152¡8 g; inf: 166¡15 g; infcv: 142¡20 g; p= 0.013). The
numbers of survivors analyzed were 15 in the control group,
six in the infected group, and eight in the carvedilol group.
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Electrocardiography
At baseline, there were no differences in heart rate, QRS
duration, or ventricular arrhythmias. The ECG at the fourth,
eighth, and eleventh months showed a decreased heart rate
in the carvedilol group, but this difference did not reach
statistical significance. However, in the control group, the
heart rate remained stable during the study, with an
increase of 0.35%, while in the infected group, it increased
by 11.5% (Figure 1). In contrast, in the carvedilol group, the
heart rate increased only 4%, demonstrating the effects of
the beta blockade. The sinus rhythm was 100% in all groups
at baseline; at the end of the study, it was 100% in the
control and infected groups and 90% in the carvedilol group
(p= 0.33). The median QRS duration at baseline was 40 msec
in all groups (p= 0.84); at the end of the study, it was
40 msec in the control and carvedilol groups and 60 msec in
the infected group (p= 0.17). Ventricular premature complex
at baseline was present in 3.7% of mice in the control group
and no mice in the infected and carvedilol groups (p= 0.26);
at the end of the study, it was present in 33% of mice in the
control and infected groups and 25% in the carvedilol group
(p= 0.37).
Myocardial remodeling
The mean ratio of heart weight over tibia length did not
show significant differences between groups, despite slightly
heavier hearts in the infected groups (C: 0.022¡0.003; inf:
0.024¡0.005; infcv: 0.026¡0.011; p= 0.804).
The left ventricular diastolic diameter was similar in all
groups at baseline. At the 11th month, there was an increase
in the ratio of left ventricular diastolic diameter over tibia
length6100 in the infected and carvedilol groups, but this
difference was not significant (C: 1.9¡0.2; inf: 2.1¡0.4;
infcv: 2.1¡0.2; p= 0.238). The ratio of systolic diameter over
tibia length6100 showed the same trend in the 11th month
(C: 1.3¡0.2; inf: 1.5¡0.5; infcv: 1.6¡0.2; p= 0.065) (Figure 2).
The collagen volume fraction of the interstitial and
perivascular space in the left and right ventricle was
increased in the infected groups compared with the control,
and there were no differences between treated and non-
treated groups (Table 1, Figure 3).
Cardiac function
Despite the reduced fractional shortening in the infected
groups, differences in the left ventricular systolic function
did not reach statistical significance in the 11th month,
although there was a slight decrease in the carvedilol-
treated group (Figure 4). The myocardial performance index
used to assess global cardiac function did not show any
significant differences between groups at the 11th month (C:
0.67¡0.12; inf: 0.58¡0.11; infcv: 0.62¡0.17; p= 0.365).
The left ventricular diastolic function was evaluated only
by CIRT, which was not significantly different between
groups.
Survival
The survival curves demonstrated significantly higher
survival in the control group compared with the infected
groups, with no differences between the treated and
untreated groups (p,0.001, Figure 5A). However, in the
acute phase (the first 100 days of infection), survival
remained better in the control group compared with the
infected groups, and the carvedilol group had better
survival compared with the infected group (p,0.001,
Figure 5B).
DISCUSSION
Several clinical trials have demonstrated the benefits of
beta-blockade on heart failure due to ischemic and
idiopathic cardiomyopathies (11,12,13). However, these
benefits have not been demonstrated for Chagas’ cardio-
myopathy. Some studies with beta-blockers included
patients with Chagas’ cardiomyopathy and showed benefits
but had small sample sizes (19,20). One study concluded
that beta-blockers were effective, not detrimental, and may
Figure 1 - The percent heart rate variation from baseline to the 11 month.
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improve survival in Chagas’ patients with chronic heart
failure and suggested that a randomized trial should be
performed to confirm these findings (21). Another study
suggested that the absence of beta-blocker use in the
treatment of Chagas’ cardiomyopathy was associated with
poor prognosis (22), and this study was the basis for other
studies (23). However, another study with small samples
presented controversial results (24). Our experimental study
was designed to evaluate the role of beta-blockade in the
context of Chagas’ disease, mainly its effects on attenuating
cardiac remodeling.
In this study, the mean body weight in the first month
was higher in the control group (p,0.003), most likely
because the animals in the infected groups lost weight
during the acute phase. However, by the 11th month, the
infected group was heavier than the control and carvedilol
groups, most likely because of a hydropic state.
Although other studies with rodents used carvedilol
doses from 2 to 30 mg/kg/day, we used 10 mg/kg/day at
the beginning and increased the dosage to 15 mg/kg/day
thereafter (beginning at six months) to ensure safety because
of the high incidence of AV blockage in Chagas’ disease.
Studies that used higher doses were mostly acute studies in
animal models other than Chagas’ cardiomyopathy. All of
the measurements showed slower heart rates in the
carvedilol group, although no significant differences were
observed. There was no reduction in ventricular arrhyth-
mias in the carvedilol group. Several studies have demon-
strated a reduction in sudden death in heart failure patients
using beta-blockers (11). However, it is possible that the
pathophysiologic mechanisms of arrhythmias in Chagas’
cardiomyopathy is related to intense myocarditis, extensive
myocardial fibrosis, and sympathetic denervation, which
may change the electrophysiological behavior of the
myocardium and may not respond to the beta-blockade
effect.
The left ventricular diastolic diameter at baseline was
similar to that found in healthy Sirius hamsters (17). No
significant dilation was observed in the infected groups,
although infected animals had larger diameters than
controls. The systolic diameter was also larger in the
infected group, but with no significant differences
(p= 0.065). This trend could represent an early stage of
cardiac dilation and dysfunction. Neither diastolic nor
systolic diameter was affected by carvedilol in the infected
groups. Another study used the same animal model and
demonstrated significant differences in ventricular diameter
(14). This difference could be because the more dilated
animals in our study died early, and not all animals will
develop dilated cardiomyopathy, even with higher myo-
cardial fibrosis.
The benefit of beta-blockers on myocardial remodeling
has been described (25). However, it was not tested
specifically in Chagas’ cardiomyopathy, which produces
intense fibrosis in myocardial tissue. Our results demon-
strate that there was major collagen accumulation in the
interstitial and perivascular space in the infected groups
and that this accumulation was not attenuated by carvedilol.
It is possible that the inflammation, autoimmune attack, and
sympathetic denervation leading to myocardial fibrosis
observed in Chagas’ disease are different from other
etiologies of cardiomyopathy. Other studies have already
demonstrated that myocardial tissue from patients with
Chagas’ cardiomyopathy contain less norepinephrine than
tissues from patients with ischemic disease.
Regarding cardiac function, although there was no sig-
nificant difference between groups, the fractional shortening
Figure 2 - Neither the left ventricular diastolic diameter index nor the left ventricular systolic index differed between groups at 11
months (p=0.238 and p=0.06, respectively).
Table 1 - Collagen volume fraction in the interstitial and
perivascular space in the left and right ventricles.
Control Infected Carvedilol p-value
Left ventricle (%) 0.81¡0.36* 4.24¡1.43 3.60¡1.90 *p,0.001
Right ventricle (%) 1.29¡0.60 5.20¡2.50* 4.42¡2.35 *p=0.002
vs control
Perivascular (%) 0.81¡0.49* 1.50¡0.40 1.41¡0.60 *p=0.013
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in infected animals was lower than previously described, and
it was not affected by carvedilol.
The survival curve showed no benefits of carvedilol
during the total period of the study. However, in the acute
phase (up to 100 days), carvedilol significantly reduced
mortality. Previously, a study of beta receptors and auto-
antibodies with atenolol as the intervention was performed
in a Chagas’ model of BALB/c mice (26). The researchers
demonstrated lower mortality in the treated group due to
decreased antibody fixation over cardiac receptors. Another
study demonstrated less parasitism in rats treated with
propranolol (9). Therefore, we speculate that a decrease in
myocarditis because of lower parasitism, together with a
decrease in the injury caused by auto-antibodies, could
explain the lower mortality observed in the acute phase.
Carvedilol may have antioxidant and anti-inflammatory
activities (27), which could also be part of this beneficial
effect in the acute phase, which is characterized by
inflammation and oxidative stress. The prevention of
sudden death with beta-blockers has been described; this
could be another plausible explanation for the decreased
mortality in the acute phase.
We conclude that carvedilol did not attenuate cardiac
remodeling or mortality in this model of Chagas’ cardio-
myopathy. The treatment did improve survival in the acute
phase of the disease.
Figure 3 - Interstitial collagen deposition in control (A), infected (B), and carvedilol groups (C). Collagen is stained in red by picrosirius
red. Collagen deposition in the perivascular space in control (D), infected (E), and carvedilol (F) groups.
Figure 4 - Fractional shortening at 11 months, with no significant differences (p=0.28).
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